This is a multi-institutional retrospective study in order to identify the most relevant and advisable features of follow-up, and to explore its impact on principal clinical outcomes. Moreover, a dedicated effort will be pursued to identify the peculiar characteristics (if any) of patients that experienced recurrence of the disease. The study will collect data about patients affected by primary GIST at very-low and low risk of recurrence/progression, referred to participating Institutions between January 2000 and February 2020
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
To describe the most relevant features of follow-up in very-low and low risk GIST patients
Timeframe: Change from diagnosis (baseline)
To describe the most relevant features of follow-up in very-low and low risk GIST patients
Timeframe: At 1 year
To describe the most relevant features of follow-up in very-low and low risk GIST patients
Timeframe: At 2 years
To describe the most relevant features of follow-up in very-low and low risk GIST patients
Timeframe: At 3 years
To describe the most relevant features of follow-up in very-low and low risk GIST patients
Timeframe: At 5 years
To evaluate the onset of other neoplasms in very-low and low risk GIST patients
Timeframe: Chage from baseline (time of diagnosis) at 5 years